Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 5mg, 10mg, 15mg, 20mg, 30mg.
The body uses several hormones to manage food, fuel and body weight. Retatrutide was designed to activate the receptors for three of them at once, and it is now in late-stage human trials.
Retatrutide (LY3437943) is a synthetic peptide designed to activate three hormone receptors at once: GLP-1, GIP and glucagon, each part of how the body responds to food and manages stored fuel. Researchers study it to learn what happens when those signals are switched on together rather than singly. Evidence comes from human trials in adults with obesity or type 2 diabetes, including phase 3 results reported in 2026; it remains an investigational compound.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 5mg | RT5 | In stock | $70 |
| 10mg | RT10 | In stock | $110 |
| 15mg | RT15 | In stock | $140 |
| 20mg | RT20 | In stock | $180 |
| 30mg | RT30 | In stock | $250 |
12 published reports for Retatrutide, listed by presentation and batch. Where a batch reference is shown, match it to the batch on the vial label; a report for an earlier batch is historical documentation and does not describe the batch currently supplied. Where no batch reference is published, the report cannot be matched to a vial and is historical documentation only. No report is published for 5mg. Each report describes the sample and the tests shown on it. A purity result does not by itself establish identity, quantity, sterility or endotoxin status unless those tests appear on the report, and a report for one batch does not describe another.
| Presentation | Report | Batch | |
|---|---|---|---|
| 10mg | manufacturer certificate | B.3.26 | Open |
| 10mg | independent laboratory report | B.3.26 | Open |
| 15mg | independent laboratory report | B.3.26, B.4.26 | Open |
| 15mg | independent laboratory report | B.3.26, B.4.26 | Open |
| 20mg | manufacturer certificate | B.4.26 | Open |
| 20mg | independent laboratory report | B.4.26 | Open |
| 30mg | manufacturer certificate | B.4.26 | Open |
| 30mg | manufacturer certificate | no batch reference published (internal label: Original (Undated),) | Open |
| 30mg | independent laboratory report | no batch reference published (internal label: Original (Undated),) | Open |
| 30mg | independent laboratory report | no batch reference published (internal label: Original (Undated),) | Open |
| 30mg | independent laboratory report | B.4.26 | Open |
| 30mg | independent laboratory report | B.4.26 | Open |
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
Retatrutide is an investigational compound. It is not an approved medicine in Australia and has not been approved by any regulator; phase 3 trials are ongoing and the sponsor has said it plans to apply for US approval in early 2027.
Status checked 2026-09-23. Details and sources in the research note.